Stabilitech Limited

Stabilitech’s research is focused on new technologies to stabilise vaccines, biopharmaceuticals and other biological products, removing the need for refrigeration Stabilitech initiated research activities in late 2004. It concluded its first significant funding round in 2007, followed by £3.3m in 2009. The company has been successful in securing non-dilutive funding with awards from the Technology Strategy Board and a $4m contract from the Defense Threat Reduction Agency (DTRA, part of the US Department of Defense).